White blood cells and severe COVID-19: a Mendelian randomization study

Yitang Sun, Jingqi Zhou, Kaixiong Ye
doi: https://doi.org/10.1101/2020.10.14.20212993

Abstract

Background The pandemic of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has rapidly emerged to seriously threaten public health. We aimed to investigate whether white blood cell traits have potential causal effects on severe COVID-19 using Mendelian randomization (MR).

Methods To evaluate the causal associations between various white blood cell traits and severe COVID-19, we conducted a two-sample MR analysis with summary statistics from recent large genome-wide association studies.

Results Our MR results indicated potential causal associations of white blood cell count, myeloid white blood cell count, and granulocyte count with severe COVID-19, with odds ratios (OR) of 0.84 (95% CI: 0.72-0.98), 0.81 (95% CI: 0.70-0.94), and 0.84 (95% CI: 0.71-0.99), respectively. Increasing eosinophil percentage of white blood cells was associated with a higher risk of severe COVID-19 (OR: 1.22, 95% CI: 1.03-1.45).

Conclusions Our results suggest the potential causal effects of lower white blood cell count, lower myeloid white blood cell count, lower granulocyte count, and higher eosinophil percentage of white blood cells on an increased risk of severe COVID-19.

  • COVID-19
  • white blood cells
  • eosinophil
  • Mendelian randomization

Background

Coronavirus disease 2019 (COVID-19) is caused by infection of a novel virus called Severe Acute Respiratory Syndrome Coronavirus 2 (SARS⍰CoV⍰2) [1]. SARS⍰CoV⍰2 has rapidly spread, causing damage or even death [2-4]. Besides age and gender, some pre-existing conditions are also well-known to be associated with an increased risk of severe COVID-19, such as cardiovascular disease, diabetes, chronic respiratory disease, hypertension, and cancers [4-7]. Recently, genetic studies, including two genome-wide association studies (GWAS), have identified multiple genetic loci to be associated with the susceptibility and severity of COVID-19 [8-10]. However, causal risk factors for severe COVID-19 remain unclear. Identifying host factors predisposing individuals to severe COVID-19 is urgently needed to improve primary prevention and to develop treatment strategies.

Elevated white blood cell and neutrophil counts, and depleted lymphocyte count have been repeatedly observed in COVID-19 patients with severe outcomes, and neutrophil-to-lymphocyte ratio have been proposed as a prognostic biomarker [1, 11-14]. However, findings from recent observational studies are inconsistent and the exact roles of white blood cells and its various subtypes in severe COVID-19 remain elusive [15-17]. Most existing studies measured blood cell counts in patients with confirmed infection of SARS-CoV-2 and as a result, the hematological indices could have been modified by immune responses [18]. It is unknown if blood cell counts before infection are associated with the risk of developing severe COVID-19. Even if white blood cells are measured before infection, they are influenced by many exogenous and endogenous factors (e.g., age, gender, disease status, and medications), which will confound the observational associations [19, 20]. No previous research has been able to interrogate the causal role of white blood cells in severe COVID-19.

While traditional observational associations often suffer from confounding, reverse causality, and various biases, a complementary approach, Mendelian randomization (MR), utilizes genetic variants as instrumental variables to approximate the lifetime status of exposure and enable causal inference in observational data. The random allocation of the allele at conception and the natural directional effects of genetic variants empower MR estimates to be less plagued by confounding and reverse causality [21, 22]. In this study, we aimed to test the causal effects of 19 white blood cell traits on severe COVID-19 by performing a two-sample MR analysis.

Methods

Study design and data source

A two-sample MR study was conducted to examine the causal effects of 19 white blood cell traits on severe COVID-19. These blood cell traits were chosen based on a GWAS meta-analysis in 173,480 European ancestry individuals across three cohorts, and their summary statistics were available in the IEU OpenGWAS database [23, 24]. Genetic instruments for each white blood cell trait were chosen based on the following criteria: 1) p < 8.31×10−9 for association with the exposure; and 2) linkage disequilibrium (LD) clumping based on r2 > 0.001. The data source and details for 19 white blood cell traits are available in Supplementary Table 1. The instrument-outcome effects were retrieved from the largest GWAS meta-analysis of COVID-19 to date, by the COVID-19 Host Genetics Initiative (HGI, release 3, accessed on July 2, 2020) [10]. We used the summary statistics based on the comparison of hospitalized COVID-19 patients (N = 3,199) with the general population (N = 897,488).

Statistical analysis

The causal effect of a white blood cell trait on severe COVID-19 was evaluated using the inverse variance-weighted (IVW) method with a multiplicative random-effects model [22, 25, 26]. Horizontal pleiotropy occurs when SNPs exert a direct effect on the severe COVD-19 through pathways other than the hypothesized exposure. To evaluate the possible presence of horizontal pleiotropy, we calculated Cochran’s Q statistic for heterogeneity and conducted the intercept test associated with the MR-Egger method. Additional sensitivity analyses were performed with MR-Egger [22, 26], weighted median (WM) [27], and Mendelian randomization pleiotropy residual sum and outlier (MR-PRESSO) test [28]. The MR-Egger estimates allowed directional or unbalanced horizontal pleiotropic effects. The weighted median method provides robust causal estimates even when up to 50 % SNPs are invalid genetic instruments [27]. The MR-PRESSO test was utilized to correct for the presence of specific horizontal pleiotropic outlier variants via detected outlier removal [28]. All MR analyses were conducted in R with the TwoSampleMR package [23].

Resources

The COVID-19 Host Genetics Initiative: https://www.covid19hg.org/

The IEU OpenGWAS database: https://gwas.mrcieu.ac.uk/

Results

The counts of white blood cell, myeloid white blood cell, and granulocyte are negatively associated with severe COVID-19

By applying a two-sample MR approach, we first investigated the causal associations of the counts of white blood cell and its subpopulations with severe COVID-19. A relatively large number of independent SNPs, ranging from 79 for basophil count to 185 for monocyte count, were selected as genetic instruments for each blood cell count (Supplementary Tables 2-11). Based on the IVW MR estimates under a multiplicative random-effects model, we identified potentially causal, negative associations of white blood cell count (OR = 0.84, CI: 0.72-0.98, p = 0.031), basophil count (OR = 0.75, CI: 0.58-0.96, p = 0.023), myeloid white blood cell count (OR = 0.81, CI: 0.70-0.94, p = 0.0070), and granulocyte count (OR = 0.84, CI: 0.71-0.99, p = 0.040) with severe COVID-19 (Fig. 1, Table 1). A suggestive negative association was also found for sum neutrophil eosinophil counts (OR = 0.85, CI: 0.73-1.00, p = 0.051). No evidence of heterogeneity in causal estimates was found by the Cochran Q statistic, and no evidence of horizontal pleiotropy was reported by the MR-Egger intercept test, except for basophil count (p = 0.036). Causal estimates from MR-Egger and WM MR revealed broadly concordant effect directions, although they are mostly not statistically significant, probably due to the reduced power of these two approaches [26] (Supplementary Fig. 1, Supplementary Table 21). MR-PRESSO analysis did not identify any outlier SNPs and yielded significant causal estimates for white blood cell count (p = 0.033), myeloid white blood cell count (p = 0.0078), and granulocyte count (p = 0.041) (Supplementary Table 21). Taken together, we demonstrated that white blood cell count, myeloid white blood cell count, and granulocyte count had consistent, negative effects on the risk of severe COVID-19.

View this table:
Table 1.

Causal associations between white blood cell traits and severe COVID-19 based on random-effects IVW MR estimation.

Figure 1.
Figure 1.

Odds ratios for associations between genetically predicted risk factors and severe COVID-19. Analyses were done with the inverse variance-weighted (IVW) method with a multiplicative random-effects model. Effect estimates express the change in odds ratio (OR) per standard deviation (SD) increment in white blood cell traits, error bars indicate 95% confidence intervals. WBC#: White blood cell count; EO#: Eosinophil count; BASO#: Basophil count; NEUT#: Neutrophil count; MONO#: Monocyte count; LYMPH#: Lymphocyte count; MYELOID#: Myeloid white blood cell count; GRAN#: Granulocyte count; (NEUT+EO)#: Sum neutrophil eosinophil counts; (BASO+NEUT)#: Sum basophil neutrophil counts; EO%: Eosinophil percentage of white blood cells; BASO%: Basophil percentage of white blood cells; NEUT%: Neutrophil percentage of white blood cells; MONO%: Monocyte percentage of white blood cells; LYMPH%: Lymphocyte percentage of white blood cells; GRAN%MYELOID: Granulocyte percentage of myeloid white blood cells; EO%GRAN: Eosinophil percentage of granulocytes; BASO%GRAN: Basophil percentage of granulocytes; NEUT%GRAN: Neutrophil percentage of granulocytes.

The percentage of eosinophil in white blood cell is positively associated with severe COVID-19

We further investigated the causal associations of the percentages of specific white blood cells with severe COVID-19. As genetic instruments, we used 158 SNPs for eosinophil percentage, 63 SNPs for basophil percentage, 135 SNPs for the neutrophil percentage, 191 SNPs for monocyte percentage, and 135 SNPs for lymphocyte percentage (Supplementary Tables 12-16).

Genetically predicted higher eosinophil percentage of white blood cells (OR = 1.22, CI: 1.03-1.45, p = 0.023) was associated with increased risk of severe COVID-19 using IVW with the random-effect model (Figure 1). The WM MR method and the MR-PRESSO analysis both revealed a consistent, positive effect (OR = 1.41, CI: 1.07-1.87, p = 0.015; and OR = 1.22, CI: 1.03-1.45, p = 0.024; respectively. Supplementary Table 21). No pleiotropy or outlier SNPs were identified in the MR-Egger test and MR-PRESSO analysis. Cochran Q statistics indicated no heterogeneity among the genetic instruments (Supplementary Table 21).

The percentage of eosinophil in granulocyte is positively associated with severe COVID-19

We further focused on the granulocyte and evaluated if it specific compositions are associated with severe COVID-19. As genetic instruments, there were 168 SNPs for granulocyte percentage of myeloid white blood cells, 150 SNPs for eosinophil percentage of granulocytes, 59 SNPs for basophil percentage of granulocytes, and 141 SNPs for the neutrophil percentage of granulocytes (Supplementary Tables 17-20). Our results found suggestive evidence for a risk-increasing effect of eosinophil percentage of granulocytes on severe COVID-19 (OR = 1.18, CI: 1.00-1.39, p = 0.053). The WM MR method and the MR-PRESSO analysis both revealed a consistent positive effect (OR = 1.35, CI: 1.03-1.75, p = 0.029; and OR = 1.18, CI: 1.00-1.39, p = 0.055; respectively). No evidence of heterogeneity and pleiotropy was found. No statistically significant causal associations were identified for other specific granulocyte percentages (Figure 1 and Supplementary Table 21).

Discussion

To our knowledge, this is the first MR study evaluating the causal roles of white blood cell traits in severe COVID-19 risk. Overall, our results suggest potential causal protective effects of increasing white blood cell count, myeloid white blood cell count, and granulocyte count on severe COVID-19. Our novel findings also include that genetically predicted higher eosinophil percentage in white blood cells or in granulocytes was associated with a higher risk of severe COVID-19.

Previous observational studies have frequently pointed out increased white blood cell count in the severe COVID-19 patients, when compared to healthy controls or mild COVID-19 patients [1, 11, 12, 29]. However, there are also reports that normal or decreased white blood cell count is more common in COVID-19 patients when compared to the reference range or healty controls [10, 15-17, 30-32]. Our MR analysis showed that lower white blood cell count, myeloid white blood cell count, and granulocyte count may play a causal role in increasing the risk of severe COVID-19. The mechanism by which they contribute to severe COVID-19 remains unclear. Immune system disorders have been suspected of playing roles in severe COVID-19 risk [33, 34]. The complete elucidation of the potential mechanism warrants further investigation.

Persistent eosinopenia after admission was associated with COVID-19 risk in previous retrospective and prospective observational studies [12, 15, 31, 32, 35-37]. There are also reports that eosinophil remains stable in severe COVID-19 patients [13, 29, 38, 39]. A multiparametric flow cytometry analysis found that high eosinophil count was associated with an increased risk of severe COVID-19 [13]. Another observational study suggested that increasing eosinophil count might be an indicator of COVID-19 improvement [40]. Our MR analysis supported that high eosinophil percentage of white blood cells may be causal in increasing the risk of severe COVID-19 [40, 41], calling for future mechanistic studies.

Lymphopenia, as a response to viral infection, has been frequently associated with severe COVID-19 risk [1, 2, 13, 29, 41-51]. However, we did not detect a causal effect of lymphocyte count on severe COVID-19. This discrepancy may reflect reverse causality in retrospective and prospective observational studies, with depleted lymphocyte count as a result of immune response to SARS⍰CoV⍰2 infection [52]. Due to the limited number of SNPs associated with severe COVID-19, performing reverse MR analyses between severe COVID-19 and white blood cell traits is challenging. Using linkage disequilibrium (LD) assessment, only one SNP at locus 3p21.31 was retained in the previously published genome-wide significant SNPs [10]. We recently showed that SNPs at this locus are associated with multiple blood cell traits, suggesting they may have pleiotropic effects and are not suitable to be used as genetic instruments [53]. As more COVID-19-associated SNPs are identified in the future, reverse MR analysis will be valuable to understand the effect of COVID-19 on blood cell traits.

One assumption of MR is that the instrumental variable influences severe COVID-19 risk only through its effect on a specific white blood cell trait. The Cochran Q statistic did not reveal heterogeneity among our genetic instruments, and the MR-Egger intercept test also indicated no presence of pleiotropic effects except those for basophil count. Our MR study was performed with strong instrumental variables and adequate statistical power, and we have conducted extensive sensitivity analyses. Still, we emphasize that our results should be interpreted with caution and future studies are needed to elucidate the mechanistic roles of white blood cell traits in severe COVID-19.

Conclusions

Our results suggest that lower white blood cell count, lower myeloid white blood cell count, lower granulocyte count, and higher eosinophil percentage of white blood cells are causally associated with an increased risk of severe COVID-19.

Data Availability

All data generated or analyzed during this study are included in this published article and this supplementary information files.

Declarations

Ethics approval and consent to participate

Ethical approval from the North West Multi-Centre Research Ethics Committee and written informed consent from all participants were obtained.

Consent for publication

Not applicable.

Availability of data and materials

All data generated or analyzed during this study are included in this published article and this supplementary information files.

Competing interests

The authors declare that they have no competing interests.

Funding

KY is supported by the University of Georgia Research Foundation. Funding sources had no involvement in the conception, design, analysis, or presentation of this work.

Authors’ contributions

YS, JZ, and KY conceived the study. YS performed data analysis and prepared visualizations. YS, JZ, and KY interpreted the results. YS and KY wrote the first draft of the manuscript. All authors critically read, revised, and approved the final version of the manuscript.

Supplemental Data

Supplementary Table 1. Summary of GWAS information for white blood cell phenotypes

Supplementary Table 2. 167 SNPs used IVs in MR analyses testing effect of white blood cell count on severe COVID-19 risk.

Supplementary Table 3. 169 SNPs used IVs in MR analyses testing effect of eosinophil count on severe COVID-19 risk.

Supplementary Table 4. 79 SNPs used IVs in MR analyses testing effect of basophil count on severe COVID-19 risk.

Supplementary Table 5. 140 SNPs used IVs in MR analyses testing effect of neutrophil count on severe COVID-19 risk.

Supplementary Table 6. 185 SNPs used IVs in MR analyses testing effect of monocyte count on severe COVID-19 risk.

Supplementary Table 7. 160 SNPs used IVs in MR analyses testing effect of lymphocyte count on severe COVID-19 risk.

Supplementary Table 8. 146 SNPs used IVs in MR analyses testing effect of myeloid white blood cell count on severe COVID-19 risk.

Supplementary Table 9. 144 SNPs used IVs in MR analyses testing effect of granulocyte count on severe COVID-19 risk.

Supplementary Table 10. 139 SNPs used IVs in MR analyses testing effect of sum neutrophil eosinophil counts on severe COVID-19 risk.

Supplementary Table 11. 142 SNPs used IVs in MR analyses testing effect of sum basophil neutrophil counts on severe COVID-19 risk.

Supplementary Table 12. 158 SNPs used IVs in MR analyses testing effect of eosinophil percentage of white blood cells on severe COVID-19 risk.

Supplementary Table 13. 63 SNPs used IVs in MR analyses testing effect of basophil percentage of white blood cells on severe COVID-19 risk.

Supplementary Table 14. 135 SNPs used IVs in MR analyses testing effect of neutrophil percentage of white blood cells on severe COVID-19 risk.

Supplementary Table 15. 191 SNPs used IVs in MR analyses testing effect of monocyte percentage of white blood cells on severe COVID-19 risk.

Supplementary Table 16. 135 SNPs used IVs in MR analyses testing effect of lymphocyte percentage of white blood cells on severe COVID-19 risk.

Supplementary Table 17. 168 SNPs used IVs in MR analyses testing effect of granulocyte percentage of myeloid white blood cells on severe COVID-19 risk.

Supplementary Table 18. 150 SNPs used IVs in MR analyses testing effect of eosinophil percentage of granulocytes on severe COVID-19 risk.

Supplementary Table 19. 59 SNPs used IVs in MR analyses testing effect of basophil percentage of granulocytes on severe COVID-19 risk.

Supplementary Table 20. 141 SNPs used IVs in MR analyses testing effect of neutrophil percentage of granulocytes on severe COVID-19 risk.

Supplementary Table 21. MR estimates from each method of assessing the causal effects of white blood cells on severe COVID-19 risk.

Supplementary Figure 1. Scatter plots of the genetic associations of white blood cell count (A), or myeloid white blood cell count (B), or granulocyte count (C), or basophil count (D) or eosinophil percentage in white blood cells (E) associated SNPs against the genetic associations of severe COVID-19. The slopes of each line represent the causal association using different MR methods. The light blue line represents the random-effects inverse variance-weighted estimate, the dark blue line represents the MR-Egger estimate, and the green line represents the weighted median estimate.

Acknowledgments

We would like to express our gratitude to all other Ye lab members for stimulating discussions.

List of abbreviations

COVID-19
coronavirus disease 2019
SARS-CoV-2
severe acute respiratory syndrome coronavirus 2
MR
Mendelian randomization
GWAS
genome-wide association studies
SNPs
single nucleotide polymorphisms
LD
linkage disequilibrium
HGI
Host Genetics Initiative
IEU
Integrative Epidemiology Unit
IVW
inverse variance-weighted
WM
weighted median
MR-PRESSO
Mendelian randomization pleiotropy residual sum and outlier

ReferencesUncategorized References

  1. 1.↵
    Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X et al: Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020, 395(10229):1054–1062.
    OpenUrlCrossRefPubMed
  2. 2.↵
    Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020, 395(10223):497–506.
    OpenUrlCrossRefPubMed
  3. 3.
    Wenham C, Smith J, Morgan R, Gender, Group C-W: COVID-19: the gendered impacts of the outbreak. Lancet 2020, 395(10227):846–848.
    OpenUrlPubMed
  4. 4.↵
    Guzik TJ, Mohiddin SA, Dimarco A, Patel V, Savvatis K, Marelli-Berg FM, Madhur MS, Tomaszewski M, Maffia P, D’Acquisto F et al: COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res 2020, 116(10):1666–1687.
    OpenUrl
  5. 5.
    Teng Y, Xu J, Zhang Y, Liu Z, Zhang S: Mendelian randomization in COVID-19: Applications for cardiovascular comorbidities and beyond. EBioMedicine 2020, 57:102847.
    OpenUrl
  6. 6.
    Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72314 Cases From the Chinese Center for Disease Control and Prevention. JAMA 2020.
  7. 7.↵
    Rao S, Lau A, So HC: Exploring Diseases/Traits and Blood Proteins Causally Related to Expression of ACE2, the Putative Receptor of SARS-CoV-2: A Mendelian Randomization Analysis Highlights Tentative Relevance of Diabetes-Related Traits. Diabetes Care 2020, 43(7):1416–1426.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    van der Made CI, Simons A, Schuurs-Hoeijmakers J, van den Heuvel G, Mantere T, Kersten S, van Deuren RC, Steehouwer M, van Reijmersdal SV, Jaeger M et al: Presence of Genetic Variants Among Young Men With Severe COVID-19. JAMA 2020.
  9. 9.
    Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fernandez J, Prati D, Baselli G, Asselta R et al: Genomewide Association Study of Severe Covid-19 with Respiratory Failure. N Engl J Med 2020.
  10. 10.↵
    Initiative C-HG: The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet 2020, 28(6):715–718.
    OpenUrl
  11. 11.↵
    Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q et al: Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020, 5(7):802–810.
    OpenUrlPubMed
  12. 12.↵
    Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, Xie C, Ma K, Shang K, Wang W et al: Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis 2020, 71(15):762–768.
    OpenUrlPubMed
  13. 13.↵
    Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR, Agyekum RS, Mathew D, Baxter AE, Vella LA et al: Comprehensive mapping of immune perturbations associated with severe COVID-19. Sci Immunol 2020, 5(49).
  14. 14.↵
    Liu J, Liu Y, Xiang P, Pu L, Xiong H, Li C, Zhang M, Tan J, Xu Y, Song R et al: Neutrophil-to-lymphocyte ratio predicts critical illness patients with 2019 coronavirus disease in the early stage. J Transl Med 2020, 18(1):206.
    OpenUrlCrossRefPubMed
  15. 15.↵
    Xie G, Ding F, Han L, Yin D, Lu H, Zhang M: The role of peripheral blood eosinophil counts in COVID-19 patients. Allergy 2020.
  16. 16.
    Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, Xiao W, Wang YN, Zhong MH, Li CH et al: Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl) 2020, 133(9):1025–1031.
    OpenUrl
  17. 17.↵
    Terpos E, Ntanasis-Stathopoulos I, Elalamy I, Kastritis E, Sergentanis TN, Politou M, Psaltopoulou T, Gerotziafas G, Dimopoulos MA: Hematological findings and complications of COVID-19. Am J Hematol 2020, 95(7):834–847.
    OpenUrlCrossRefPubMed
  18. 18.↵
    Siedlinski M, Jozefczuk E, Xu X, Teumer A, Evangelou E, Schnabel RB, Welsh P, Maffia P, Erdmann J, Tomaszewski M et al: White Blood Cells and Blood Pressure: A Mendelian Randomization Study. Circulation 2020, 141(16):1307–1317.
    OpenUrl
  19. 19.↵
    Zhang X, Tan Y, Ling Y, Lu G, Liu F, Yi Z, Jia X, Wu M, Shi B, Xu S et al: Viral and host factors related to the clinical outcome of COVID-19. Nature 2020, 583(7816):437–440.
    OpenUrl
  20. 20.↵
    Zhao K, Li R, Wu X, Zhao Y, Wang T, Zheng Z, Zeng S, Ding X, Nie H: Clinical features in 52 patients with COVID-19 who have increased leukocyte count: a retrospective analysis. Eur J Clin Microbiol Infect Dis 2020.
  21. 21.↵
    Davies NM, Holmes MV, Davey Smith G: Reading Mendelian randomisation studies: a guide, glossary, and checklist for clinicians. BMJ 2018, 362:k601.
    OpenUrlFREE Full Text
  22. 22.↵
    Burgess S, Davey Smith G, Davies N, Dudbridge F, Gill D, Glymour M, Hartwig F, Holmes M, Minelli C, Relton C et al: Guidelines for performing Mendelian randomization investigations [version 2; peer review: 1 approved, 1 approved with reservations]. Wellcome Open Research 2020, 4(186).
  23. 23.↵
    Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D, Laurin C, Burgess S, Bowden J, Langdon R et al: The MR-Base platform supports systematic causal inference across the human phenome. Elife 2018, 7.
  24. 24.↵
    Astle WJ, Elding H, Jiang T, Allen D, Ruklisa D, Mann AL, Mead D, Bouman H, Riveros-Mckay F, Kostadima MA et al: The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease. Cell 2016, 167(5):1415–1429 e1419.
    OpenUrlCrossRefPubMed
  25. 25.↵
    Burgess S, Butterworth A, Thompson SG: Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol 2013, 37(7):658–665.
    OpenUrlCrossRefPubMed
  26. 26.↵
    Bowden J, Davey Smith G, Burgess S: Mendelian randomization with invalid instruments: effect estimation and bias detection through Egger regression. Int J Epidemiol 2015, 44(2):512–525.
    OpenUrlCrossRefPubMed
  27. 27.↵
    Bowden J, Davey Smith G, Haycock PC, Burgess S: Consistent Estimation in Mendelian Randomization with Some Invalid Instruments Using a Weighted Median Estimator. Genet Epidemiol 2016, 40(4):304–314.
    OpenUrlCrossRefPubMed
  28. 28.↵
    Verbanck M, Chen CY, Neale B, Do R: Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet 2018, 50(5):693–698.
    OpenUrlCrossRefPubMed
  29. 29.↵
    Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, Akdis CA, Gao YD: Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020, 75(7):1730–1741.
    OpenUrlCrossRefPubMed
  30. 30.↵
    Zhou Y, Fu B, Zheng X, Wang D, Zhao C, qi Y, Sun R, Tian Z, Xu X, Wei H: Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl Sci Rev 2020:waa041.
  31. 31.↵
    Sun DW, Zhang D, Tian RH, Li Y, Wang YS, Cao J, Tang Y, Zhang N, Zan T, Gao L et al: The underlying changes and predicting role of peripheral blood inflammatory cells in severe COVID-19 patients: A sentinel?Clin Chim Acta 2020, 508:122–129.
    OpenUrl
  32. 32.↵
    Li Q, Ding X, Xia G, Chen HG, Chen F, Geng Z, Xu L, Lei S, Pan A, Wang L et al: Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: A retrospective case-control study. EClinicalMedicine 2020, 23:100375.
    OpenUrl
  33. 33.↵
    Jesenak M, Brndiarova M, Urbancikova I, Rennerova Z, Vojtkova J, Bobcakova A, Ostro R, Banovcin P: Immune Parameters and COVID-19 Infection - Associations With Clinical Severity and Disease Prognosis. Front Cell Infect Microbiol 2020, 10:364.
    OpenUrl
  34. 34.↵
    Azkur AK, Akdis M, Azkur D, Sokolowska M, van de Veen W, Bruggen MC, O’Mahony L, Gao Y, Nadeau K, Akdis CA: Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19. Allergy 2020, 75(7):1564–1581.
    OpenUrlCrossRefPubMed
  35. 35.↵
    Wang D, Li R, Wang J, Jiang Q, Gao C, Yang J, Ge L, Hu Q: Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study. BMC Infect Dis 2020, 20(1):519.
    OpenUrl
  36. 36.
    Gong J, Dong H, Xia SQ, Huang YZ, Wang D, Zhao Y, Liu W, Tu S, Zhang M, Wang Q et al: Correlation Analysis Between Disease Severity and Inflammation-related Parameters in Patients with COVID-19 Pneumonia. 2020:2020.2002.2025.20025643.
  37. 37.↵
    Tanni F, Akker E, Zaman MM, Figueroa N, Tharian B, Hupart KH: Eosinopenia and COVID-19. J Am Osteopath Assoc 2020.
  38. 38.↵
    Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, Shi CW, Lian X, Chu JG, Chen L et al: Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series. QJM 2020, 113(7):474–481.
    OpenUrlPubMed
  39. 39.↵
    Lippi G, Henry BM: Eosinophil count in severe coronavirus disease 2019.QJM 2020, 113(7):511–512.
    OpenUrl
  40. 40.↵
    Liu F, Xu A, Zhang Y, Xuan W, Yan T, Pan K, Yu W, Zhang J: Patients of COVID-19 may benefit from sustained Lopinavir-combined regimen and the increase of Eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis 2020, 95:183–191.
    OpenUrlPubMed
  41. 41.↵
    Sun S, Cai X, Wang H, He G, Lin Y, Lu B, Chen C, Pan Y, Hu X: Abnormalities of peripheral blood system in patients with COVID-19 in Wenzhou, China. Clin Chim Acta 2020, 507:174–180.
    OpenUrl
  42. 42.
    Vabret N, Britton GJ, Gruber C, Hegde S, Kim J, Kuksin M, Levantovsky R, Malle L, Moreira A, Park MD et al: Immunology of COVID-19: Current State of the Science. Immunity 2020, 52(6):910–941.
    OpenUrlPubMed
  43. 43.
    Rothan HA, Byrareddy SN: The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun 2020, 109:102433.
    OpenUrlCrossRefPubMed
  44. 44.
    Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al: Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020, 323(11):1061–1069.
    OpenUrlCrossRefPubMed
  45. 45.
    Ding Q, Lu P, Fan Y, Xia Y, Liu M: The clinical characteristics of pneumonia patients coinfected with 2019 novel coronavirus and influenza virus in Wuhan, China. J Med Virol 2020.
  46. 46.
    Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC et al: Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020, 382(18):1708–1720.
    OpenUrlCrossRefPubMed
  47. 47.
    Han R, Huang L, Jiang H, Dong J, Peng H, Zhang D: Early Clinical and CT Manifestations of Coronavirus Disease 2019 (COVID-19) Pneumonia. AJR Am J Roentgenol 2020, 215(2):338–343.
    OpenUrlPubMed
  48. 48.
    Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, Dai J, Sun Q, Zhao F, Qu J et al: Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect 2020, 80(4):388–393.
    OpenUrlPubMed
  49. 49.
    Zhang MQ, Wang XH, Chen YL, Zhao KL, Cai YQ, An CL, Lin MG, Mu XD: [Clinical features of 2019 novel coronavirus pneumonia in the early stage from a fever clinic in Beijing]. Zhonghua Jie He He Hu Xi Za Zhi 2020, 43(0):E013.
    OpenUrlPubMed
  50. 50.
    Peng YD, Meng K, Guan HQ, Leng L, Zhu RR, Wang BY, He MA, Cheng LX, Huang K, Zeng QT: [Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV]. Zhonghua Xin Xue Guan Bing Za Zhi 2020, 48(6):450–455.
    OpenUrl
  51. 51.↵
    Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, Lang C, Huang D, Sun Q, Xiong Y et al: Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol 2020, 92(7):797–806.
    OpenUrlCrossRefPubMed
  52. 52.↵
    Sattar N, Preiss D: Reverse Causality in Cardiovascular Epidemiological Research: More Common Than Imagined?Circulation 2017, 135(24):2369–2372.
    OpenUrlFREE Full Text
  53. 53.↵
    Zhou J, Sun Y, Huang W, Ye K: Altered blood cell traits underlie a major genetic locus of severe COVID-19. doi:2020:2020.2009.2009.20191700.
    OpenUrlCrossRef
Back to top
Posted October 18, 2020.
Download PDF

Supplementary Material

Data/Code
Email
White blood cells and severe COVID-19: a Mendelian randomization study
Yitang Sun, Jingqi Zhou, Kaixiong Ye
medRxiv 2020.10.14.20212993; doi: https://doi.org/10.1101/2020.10.14.20212993
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area